<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530175</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2020 ANIORT</org_study_id>
    <secondary_id>2020-A01359-30</secondary_id>
    <nct_id>NCT04530175</nct_id>
  </id_info>
  <brief_title>Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)</brief_title>
  <acronym>MARC</acronym>
  <official_title>Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to validate a mathematical modeling of treatment by&#xD;
      intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing&#xD;
      calcium&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only visit to the study will be carried out during a usual dialysis session in the&#xD;
      intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2&#xD;
      blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis&#xD;
      session by the nurse in charge of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ionized calcium level</measure>
    <time_frame>day 0</time_frame>
    <description>measured at dialyzer inlet, in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total calcium level</measure>
    <time_frame>day 0</time_frame>
    <description>measured at dialyzer inlet, in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total citratemia</measure>
    <time_frame>day 0</time_frame>
    <description>measured at dialyzer inlet, in mmol/L</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>patients with hemodialysis</arm_group_label>
    <description>patient treated with intermittent hemodialysis for chronic renal failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.</description>
    <arm_group_label>patients with hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated with intermittent hemodialysis for chronic renal failure, at university&#xD;
        hospital of Clermont-Ferrand&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient;&#xD;
&#xD;
          -  Man or woman ;&#xD;
&#xD;
          -  Treated with intermittent hemodialysis for chronic renal failure;&#xD;
&#xD;
          -  In whom intermittent hemodialysis with citrate solution for regional anticoagulation&#xD;
             is indicated;&#xD;
&#xD;
          -  Affiliated with a social security scheme;&#xD;
&#xD;
          -  Having given a signed agreement after detailed explanation of the protocol on the&#xD;
             basis of the information sheet and likely to comply with it&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hepato-cellular insufficiency (PT &lt;50%, INR&gt; 1.5 without anticoagulant);&#xD;
&#xD;
          -  Hemoglobin level &lt;7 g / dL&#xD;
&#xD;
          -  Presenting a psychiatric pathology or cognitive impairment rendering him unable to&#xD;
             give informed consent;&#xD;
&#xD;
          -  Persons under guardianship, curatorship, deprived of liberty or safeguard of justice&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patient's refusal to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Aniort</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>+33473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien Aniort</last_name>
      <email>janiort@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>modeling</keyword>
  <keyword>Citrate anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

